A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study

BACKGROUND: Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could...

Descripción completa

Detalles Bibliográficos
Autores principales: Español-Rego, Marta, Fernández-Martos, Carlos, Elez, Elena, Foguet, Carles, Pedrosa, Leire, Rodríguez, Nuria, Ruiz-Casado, Ana, Pineda, Estela, Cid, Joan, Cabezón, Raquel, Oliveres, Helena, Lozano, Miquel, Ginés, Angels, García-Criado, Angeles, Ayuso, Juan Ramon, Pagés, Mario, Cuatrecasas, Miriam, Torres, Ferràn, Thomson, Timothy, Cascante, Marta, Benítez-Ribas, Daniel, Maurel, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025226/
https://www.ncbi.nlm.nih.gov/pubmed/36083313
http://dx.doi.org/10.1007/s00262-022-03283-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025226/
https://www.ncbi.nlm.nih.gov/pubmed/36083313
http://dx.doi.org/10.1007/s00262-022-03283-5

Ejemplares similares